Midostaurin

LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY

Retrieved on: 
Friday, November 11, 2022
Asian Business Case Competition @ Nanyang, EPS, Rheumatoid arthritis, Company, LTM, RA, Korean won, Total, Gefitinib, Tadalafil, Growth, Record, Partnership, Enzalutamide, Sunitinib, Pharmaceutical industry, Video game, Drug, Airline, Fine chemical, Renewable energy, Vinorelbine, Lenalidomide, Lotus, Midostaurin

Third quarter 2022 is the best quarter ever in the Company's history, majorly driven by the successful launch of Lenalidomide in the US the biggest launch in Lotus history so far.

Key Points: 
  • Third quarter 2022 is the best quarter ever in the Company's history, majorly driven by the successful launch of Lenalidomide in the US the biggest launch in Lotus history so far.
  • Consolidated net sales were NT$5,389 million, representing a growth of 85.2% over the last quarter and 76.3% versus prior year period.
  • Sales from Export increased 245% compared to last quarter and 183% compared to same period last year.
  • Asian Business continued to grow for the third consecutive quarter, 3.2% over last quarter, also 10.8% over the same period last year.

LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY

Retrieved on: 
Friday, November 11, 2022
Asian Business Case Competition @ Nanyang, EPS, Rheumatoid arthritis, Company, LTM, RA, Korean won, Total, Gefitinib, Tadalafil, Growth, Record, Partnership, Enzalutamide, Sunitinib, Pharmaceutical industry, Video game, Drug, Airline, Fine chemical, Renewable energy, Vinorelbine, Lenalidomide, Lotus, Midostaurin

Third quarter 2022 is the best quarter ever in the Company's history, majorly driven by the successful launch of Lenalidomide in the US the biggest launch in Lotus history so far.

Key Points: 
  • Third quarter 2022 is the best quarter ever in the Company's history, majorly driven by the successful launch of Lenalidomide in the US the biggest launch in Lotus history so far.
  • Consolidated net sales were NT$5,389 million, representing a growth of 85.2% over the last quarter and 76.3% versus prior year period.
  • Sales from Export increased 245% compared to last quarter and 183% compared to same period last year.
  • Asian Business continued to grow for the third consecutive quarter, 3.2% over last quarter, also 10.8% over the same period last year.

Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting

Retrieved on: 
Friday, June 11, 2021
Chemical compounds, Tyrosine kinase receptors, Protein kinase inhibitors, Organic compounds, AXL receptor tyrosine kinase, Heterocyclic compounds, Bemcentinib, Orphan drugs, CD135, Midostaurin

An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.

Key Points: 
  • An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.
  • The data indicate that the combination of bemcentinib, a once-daily oral AXL-inhibitor and LDAC is efficacious and well tolerated in the elderly and unfit relapsed AML population.
  • Ongoing dialogue continues with the FDA and EMA regulatory agenciesto align on a pathway for apivotalregistration trial for the combination ofbemcentinibandLDAC in relapsed elderly AML patients unfit for intensive chemotherapy.
  • Data from a Phase II in human clinical trial has shown that treatment with AXL inhibitor bemcentinib increased the rate ventilator free survival in hospitalised COVID-19 patients.

Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting

Retrieved on: 
Friday, June 11, 2021
Chemical compounds, Tyrosine kinase receptors, Protein kinase inhibitors, Organic compounds, AXL receptor tyrosine kinase, Heterocyclic compounds, Bemcentinib, Orphan drugs, CD135, Midostaurin

An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.

Key Points: 
  • An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.
  • The data indicate that the combination of bemcentinib, a once-daily oral AXL-inhibitor and LDAC is efficacious and well tolerated in the elderly and unfit relapsed AML population.
  • Ongoing dialogue continues with the FDA and EMA regulatory agenciesto align on a pathway for apivotalregistration trial for the combination ofbemcentinibandLDAC in relapsed elderly AML patients unfit for intensive chemotherapy.
  • Data from a Phase II in human clinical trial has shown that treatment with AXL inhibitor bemcentinib increased the rate ventilator free survival in hospitalised COVID-19 patients.

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

Retrieved on: 
Monday, June 7, 2021
Tyrosine kinase receptors, CD135, Midostaurin

IND clearance by the FDA paves the way to test a differentiated treatment approach by targeting extracellular FLT3, an oncogenic driver in AML, stated Patrick Baeuerle, Cullinans Chief Scientific Officer, Biologics.

Key Points: 
  • IND clearance by the FDA paves the way to test a differentiated treatment approach by targeting extracellular FLT3, an oncogenic driver in AML, stated Patrick Baeuerle, Cullinans Chief Scientific Officer, Biologics.
  • We are excited to initiate human dosing of CLN-049, a T cell-engaging, IgG-like antibody in patients with relapsed/refractory AML.
  • CLN-049is a humanized bispecific antibody being developed for relapsed/refractory AML.
  • In preclinical studies, CLN-049led to potent FLT3-dependent killing of leukemic cellsin vitroat a wide range of FLT3 expression levels on AML cells.

Aptose to Hold Corporate Update Friday, June 11th

Retrieved on: 
Thursday, May 27, 2021
Enzymes, Branches of biology, Tyrosine kinases, CD135, Acute myeloid leukemia, Cell signaling, Myelodysplastic syndrome, Bruton's tyrosine kinase, Protein kinase inhibitors, Antibody-drug conjugates, Midostaurin, Devimistat

SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.

Key Points: 
  • SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.
  • The event will include an up-to-date review of clinical data available for Aptoses clinical programs: luxeptinib (CG-806), Aptoses oral, first-in-class FLT3 and BTK kinase inhibitor in two Phase 1 a/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies; and APTO-253, a first-in-class small molecule MYC repressor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndromes (MDS).

Aptose to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 12, 2021
Myelodysplastic syndrome, Tumors of the hematopoietic and lymphoid tissues, Clinical medicine, Medicine, Cancer, Devimistat, Midostaurin

b"The Aptose management team also will be hosting 1x1 meetings during the events.\nAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.

Key Points: 
  • b"The Aptose management team also will be hosting 1x1 meetings during the events.\nAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.
  • The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
  • The Company has two clinical-stage investigational products for hematologic malignancies.
  • The second investigational product, APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).\n"

BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020

Retrieved on: 
Sunday, December 6, 2020
Chemical compounds, Protein kinase inhibitors, Tyrosine kinase receptors, AXL receptor tyrosine kinase, Bemcentinib, Organic compounds, Heterocyclic compounds, 7+3, Midostaurin

The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.

Key Points: 
  • The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.
  • Richard Godfrey, Chief Executive Officer of BerGenBio, said: "We are pleased to continue sharing updates from our phase II clinical studies assessing bemcentinib with the scientific and medical community.
  • MDS is associated with increased risk of developing AML and immune dysfunctions are seen in patients both with lower and higher-risk MDS.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020

Retrieved on: 
Sunday, December 6, 2020
Chemical compounds, Protein kinase inhibitors, Tyrosine kinase receptors, AXL receptor tyrosine kinase, Bemcentinib, Organic compounds, Heterocyclic compounds, 7+3, Midostaurin

The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.

Key Points: 
  • The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.
  • Richard Godfrey, Chief Executive Officer of BerGenBio, said: "We are pleased to continue sharing updates from our phase II clinical studies assessing bemcentinib with the scientific and medical community.
  • MDS is associated with increased risk of developing AML and immune dysfunctions are seen in patients both with lower and higher-risk MDS.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

Syros to Present New Data from Phase 2 Clinical Trial of SY-1425 in Oral Presentations at 62nd ASH Annual Meeting

Retrieved on: 
Wednesday, November 4, 2020
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Orphan drugs, Lactams, Chemical compounds, Organic compounds, Drugs, Nucleosides, Triazines, Acute myeloid leukemia, 7+3, Azacitidine, Antibody-drug conjugates, Midostaurin

The oral presentations will include data on SY-1425 in combination with azacitidine from a cohort of RARA-positive patients with relapsed or refractory acute myeloid leukemia (AML) and mature data on the combination in newly diagnosed unfit AML patients who are not suitable candidates for standard chemotherapy.

Key Points: 
  • The oral presentations will include data on SY-1425 in combination with azacitidine from a cohort of RARA-positive patients with relapsed or refractory acute myeloid leukemia (AML) and mature data on the combination in newly diagnosed unfit AML patients who are not suitable candidates for standard chemotherapy.
  • Syros is advancing a robust pipeline, including SY-1425, a first-in-class oral selective RAR agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in a Phase 1 trial in patients with select solid tumors.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
  • For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.